Accueil>>Signaling Pathways>> Proteases>> Drug Metabolite>>Quetiapine sulfoxide dihydrochloride

Quetiapine sulfoxide dihydrochloride

Catalog No.GC37057

Le dichlorhydrate de sulfoxyde de quétiapine (dichlorhydrate de quetiapine S-oxyde) est un métabolite principal de la quétiapinem.

Products are for research use only. Not for human use. We do not sell to patients.

Quetiapine sulfoxide dihydrochloride Chemical Structure

Cas No.: 329218-11-3

Taille Prix Stock Qté
5mg
167,00 $US
En stock
10mg
278,00 $US
En stock
50mg
1 205,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Quetiapine sulfoxide dihydrochloride (Quetiapine S-oxide dihydrochloride) is a main metabolite of Quetiapinem. Quetiapine is a second-generation antipsychotic[1].

The Cmax value (mean±SD) is estimated for Quetiapine sulfoxide (77.3±32.4 ng/mL). The AUClast value is estimated for Quetiapine sulfoxide (1,286±458 ng•h/mL). For Quetiapine sulfoxide, metabolic ratio decreases with time, from 119% on average 2 hours after dosing to 30% on average 72 hours after dosing[1].

[1]. Remmerie B, et al. Comparison of Capillary and Venous Drug Concentrations After Administration of a Single Dose of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole. Clin Pharmacol Drug Dev. 2016 Nov;5(6):528-537.

Avis

Review for Quetiapine sulfoxide dihydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 35 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Quetiapine sulfoxide dihydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.